On March 27, 2026, BullFrog AI Holdings, Inc. entered into a feasibility agreement with a global pharmaceutical company to utilize their AI tool, bfLEAP®, for drug candidate discovery related to major depressive disorder, potentially earning milestone payments. The agreement lasts one year and includes terms for exclusivity on a selected drug candidate.